While both AD and FTLD-tau show pronounced tau pathology, there are distinct differences in p-tau deposition between AD and FTLD-tau in regards to affected neuronal and glial cell types and in regards to the spatio-temporal distribution of p-tau aggregates in the brains. This evidence concerns the gene MAPT and Alzheimer disease.